Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP505 in advanced solid tumors
NCT06723964Phase 1Active, not recruiting
- Sponsor
- AP Biosciences
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of B1962 in solid tumor (advanced stage), sponsored by AP Biosciences. Primary endpoints: Dose-Limiting Toxicity, Adverse Events and 2 more. Started Mar 2023; status: active, not recruiting.
02
Drugs
B1962
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06723964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723964.